Lichen sclerosus
Also known as: LS, Vulvar lichen sclerosus, Anogenital lichen sclerosus, Extragenital lichen sclerosus, Lichen sclerosus et atrophicus
Lichen sclerosus is a chronic inflammatory dermatosis characterised by atrophic, porcelain-white plaques predominantly affecting the anogenital region, though extragenital disease also occurs. Clinical manifestations including pruritus, discomfort, and tissue changes can impair daily functioning and sexual wellbeing. Medical assessment, prescribed topical corticosteroids, and long-term surveillance remain central, particularly due to the risk of progression to squamous cell carcinoma. Traditional Chinese Medicine (TCM) diagnostic frameworks may offer an adjunctive approach for symptom support; however, current evidence does not support the efficacy of acupuncture or Chinese herbal formulas in this condition. While investigations into genetic targets and a single case report on upadacitinib exist, they do not establish routine treatment benefit. TCM patterns remain conceptual models, not validated clinical subtypes or substitutes for specialist care.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Utilise pH-neutral, non-soap cleansers and avoid fragranced products or mechanical irritation of the affected epithelium.
- •Prioritise non-restrictive clothing and modify activities that induce repetitive friction or exacerbate cutaneous soreness.
- •Maintain a brief record of pruritus, pain, sleep disturbance, and visible skin changes to discuss at clinical reviews, avoiding repeated manipulation of the skin.
- •Ensure strict compliance with all scheduled clinical reviews and oncological surveillance; report sexual dysfunction or psychological distress to the treating multidisciplinary team.
Cautions & Contraindications
- •Do not replace or discontinue prescribed topical corticosteroids or long-term surveillance in favour of acupuncture or herbs. The supplied bibliometric review identifies corticosteroids as primary treatment and notes carcinoma risk; it is not a detailed prescribing guideline.[]
- •Do not needle, massage or apply unassessed herbal preparations to a new ulcer, thickened lesion or bleeding area before medical assessment. This is a precaution based on the malignancy concern identified in the supplied review, not a needling protocol tested in that study.[]
- •Do not use the single upadacitinib case report to justify starting, stopping or changing systemic medicines, or combining them with herbs without prescriber review. It provides no evidence about herbal interactions or combination safety.[]
- •Do not present genetically inferred targets or molecular docking results as evidence that a drug, supplement or herbal product is clinically effective or safe for lichen sclerosus.[]
When to reassess or seek care again
If adjunctive care is agreed, review after 2–4 weeks using baseline and repeat 0–10 itch and pain scores, nights of disturbed sleep per week, tolerability and functional impact. Record prescribed-treatment adherence without changing the medical regimen. Stop or reconsider adjunctive treatment if symptoms worsen, adverse effects occur or there is no meaningful improvement after 4–6 weeks. New suspicious lesions require prompt specialist assessment rather than waiting for this interval. Continue clinician-directed long-term surveillance regardless of symptom improvement.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.Frontiers in immunology · 2026
- Global medical genetics · 2026
- Journal of the American Academy of Dermatology · 2026
- Health science reports · 2025
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
